Sumatriptan alleviates pain in patients with trigeminal neuralgia

Clinical Journal of Pain

Volumn 22, Issue 8, 2006, Pages 677-680

  Kanai, Akifumi ^a,b   Suzuki, Asaha ^a   Osawa, Satoru ^a   Hoka, Sumio ^a  

^a KITASATO UNIVERSITY   (Japan)

^b KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Sumatriptan; Trigeminal neuralgia; Visual analog scale

Indexed keywords

CARBAMAZEPINE; SUMATRIPTAN; TRIPTAN DERIVATIVE;

ADULT; AGED; ALLODYNIA; ANALGESIA; ARTICLE; CLINICAL ARTICLE; FATIGUE; FEMALE; HUMAN; INFLAMMATION; MALE; NAUSEA; NERVE COMPRESSION; PRIORITY JOURNAL; THORAX PAIN; TRIGEMINUS NEURALGIA; UNSPECIFIED SIDE EFFECT; VASODILATATION; VISUAL ANALOG SCALE;

ADULT; AGED; AGED, 80 AND OVER; ANALGESICS; FEMALE; HUMANS; MALE; MIDDLE AGED; PAIN; PAIN MEASUREMENT; SUMATRIPTAN; TREATMENT OUTCOME; TRIGEMINAL NEURALGIA;

EID: 33748937219     PISSN: 07498047     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ajp.0000210917.18536.0d     Document Type: Article

References (18)

1. Rozen TD. Antiepileptic drugs in the management of cluster headache and trigeminal neuralgia. Headache. 2000;41:S25-S32.
2. Barker FG II, Jannetta PJ, Bissonette DJ, et al. The long-term outcome of microvascular decompression for trigeminal neuralgia. N Engl J Med. 1996;334:1077-1083.
3. Blom S. Trigeminal neuralgia: its treatment with a new anti-convulsant drug (G-32883). Lancet. 1962;i:839-840.
4. 1B/1D agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet. 2001;358:1668-1675.
5. Fowler PA, Lacey LF, Thomas M, et al. The clinical pharmacology, pharmacokinetics and metabolism of sumatriptan. Eur Neurol. 1991;31:291-294.
6. Pfaffenrath V, Cunin G, Sjonell G, et al. Efficacy and safety of sumatriptan tablets (25 mg, 50 mg, 100 mg) in the acute treatment of migraine: defining the optimum doses of oral supatriptan. Headache. 1998;38:184-190.
7. Savani N, Brautaset NJ, Reunanen M, et al. A double-blind placebo-controlled study assessing the efficacy and tolerability of 50mg sumatriptan tablets in the acute treatment of migraine. Sumatriptan Tablets S2CM07 Study Group. Int J Clin Pract. 1999;105(Suppl):7-15.
8. 1A receptor activation: a new mechanism of profound central analgesia. Neuropharmacology. 2002;43:945-958.
9. Bouchelet I, Cohen Z, Case B, et al. Differential expression of sumatriptan-sensitive 5-hydroxy-tryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol Pharmacol. 1996;50:219-223.
10. Limmroth V, Katsarava Z, Liedert B, et al. An in vivo rat model to study calcitonin gene related peptide release following activation of the trigeminal vascular system. Pain. 2001;92:101-106.
11. Waltz TA, Dalessio DJ, Copeland B, et al. Percutaneous injection of glycerol for the treatment of trigeminal neuralgia. Clin J Pain. 1989;5:195-198.
12. Hara H, Kobayashi S. Glycerol injection to the rat trigeminal nerve: histological and immunohistochemical studies. Acta Neurochir (Wien). 1992;119:111-114.
13. O'Connor TP, van der Kooy D. Enrichment of a vasoactive neuropeptide (calcitonin gene-related peptide) in the trigeminal sensory projection to the intracranial arteries. J Neurosci. 1988;8:2468-2476.
14. Le Greves P, Nyberg F, Terenius L, et al. Calcitonin gene-related peptide is a potent inhibitor of substance P degradation. Eur J Pharmacol. 1985;115:309-311.
15. Oku R, Satoh M, Fujii N, et al. Calcitonin gene-related peptide promotes mechanical nociception by potentiating release of substance P from the spinal dorsal horn in rats. Brain Res. 1987;403:350-354.
16. Goadsby PJ, Edvinsson L, Ekman R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann Neurol. 1988;23:193-196.
17. Strittmatter M, Grauer M, Isenberg E, et al. Cerebrospinal fluid neuropeptides and monoaminergic transmitters in patients with trigeminal neuralgia. Headache. 1997;37:211-216.
18. Love S, Coakham HB. Trigeminal neuralgia: pathology and pathogenesis. Brain. 2001;124:2347-2360.